Subclass mapping demonstrated that glioma patients with the high-risk subtype were more sensitive to anti-PD1 therapy in the TCGA, CGGA, GSE16011 cohort, with Bonferroni P = 0.007, 0.032, and 0.046, respectively (Figure 7H and Supplementary Figures S10C, F). This evidence concerns the gene PDCD1 and glioma.